Megasoft Limited has informed the Exchange regarding Outcome of Board Meeting held on July 01, 2025.
SIGMAADV · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Megasoft Limited's board, at a meeting held on July 1, 2025, approved the sale of its 36.52% holding in associate company Extrovis AG, Switzerland. The buyer is Refex Life Sciences Private Limited, which is not a related party. The total consideration is US $15 million (approximately INR 128.40 Crores), payable in one or more tranches, subject to forex fluctuations and final agreement terms. The Sale/Purchase Agreement is yet to be executed, and the company will seek shareholder approval through a postal ballot. Since Extrovis AG is an associate, the sale has no impact on standalone financials but only on consolidated numbers.
This is a significant asset sale worth ~INR 128 Crores for Megasoft. Proceeds could strengthen the company's cash position and may be deployed toward growth or debt reduction. Shareholders should watch for the SPA execution and postal ballot outcome in the coming weeks.